🟢 Scholar Rock is trading 4.25% up today with biotech sector up 2.10%

Scholar Rock is trading at $43.12, up 4.25%, with the biotech sector’s 2.10% gain the clearest available context.

• No major new company-specific announcement was found for October 21.
• Truist reiterated its Buy rating and $77 price target, citing physician feedback on Isembyld’s uptake potential. The coverage was reported around October 20–21 and is not a confirmed explanation for the full move.
• The supplied information does not include trading volume.